According to IMS Health sales data for the 12 month period ending October 2015, the Zyvox Tablets, 600 mg market achieved annual sales of approximately $447.6 million.
According to IMS Health sales data for the 12 month period ending October 2015, the Zyvox Tablets, 600 mg market1 achieved annual sales of approximately $447.6 million.
Glenmark's current portfolio consists of 104 products authorized for distribution in the U.S. marketplace and 62 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
All brand names and trademarks are the property of their respective owners. Market includes brand and all available therapeutic equivalents IMS Health National Sales Perspectives: Retail & Non-Retail, October 2015.
Glenmark Pharmaceuticals Ltd is currently trading at Rs. 946.55, up by Rs. 19.15 or 2.06% from its previous closing of Rs. 927.4 on the BSE.
The scrip opened at Rs. 929 and has touched a high and low of Rs. 950 and Rs. 921.4 respectively. So far 239672(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 26167.35 crore.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1261.95 on 21-Aug-2015 and a 52 week low of Rs. 703.5 on 07-Jan-2015. Last one week high and low of the scrip stood at Rs. 935 and Rs. 853 respectively.
The promoters holding in the company stood at 46.45 % while Institutions and Non-Institutions held 42.81 % and 10.75 % respectively.
The stock is currently trading above its 100 DMA.
No comments:
Post a Comment